Treatment of emergent peripheral neuropathy in plasma cell disorders
Myeloma: Pathology, Diagnosis, and Treatment, Page: 245-254
2011
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Introduction Peripheral neuropathy (PN) occurs due to damage, inflammation or dysfunction to the peripheral nervous system, most likely as a result of injury to axons, myelin sheaths or the cell bodies. The extent of impaired function depends on the type of nerves affected – motor, sensory or autonomic. The onset of symptoms is variable and can present gradually or in a more rapid fashion. Symptoms range from temporary numbness, tingling, paresthesias, sensitivity to touch and weakness to more severe symptoms ranging from burning pain, muscle wasting, and to the extent of paralysis[1,2]. Typically, the longest nerves in the extremities are first affected with symmetric length dependent spreading from distal to proximal nerves[3]. The most common clinical manifestation of PN occurs in a “stocking and glove” pattern and the patients may complain of losing hand grip by dropping things or having difficulty picking up small objects. Patients with autonomic symptoms may experience labile blood pressure changes, orthostatic hypotension, irregular heart rates, changes in gastrointestinal motility, swallowing or respiratory problems[2]. PN tends to have a severe impact on quality of life and functional abilities in cancer patients and can impact overall survival or severity of full dose effective therapy[1].
Bibliographic Details
Cambridge University Press (CUP)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know